Marqibo vincristine: Phase II data

Data from the open-label, international, pivotal Phase II rALLy trial in 56 patients with relapsed Philadelphia chromosome-negative ALL in second relapse showed that 2.25 mg/m 2 once-weekly IV Marqibo had an overall response rate (ORR) of 36%, with 21% of patients achieving a CR or CRi. Estimated median OS was 4.6 months for all 56 patients and 7.3 months in complete responders. Data were presented at the American Society of Hematology meeting in New Orleans. ...